Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
625 stopped studies mapped to Malignant Urinary System Neoplasm and descendants · 88% state a reason
Over the 625 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01688414 | Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer | N/A | withdrawn | Sep 19, 2012 | Stanford University | PI left Stanford | Investigator |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With… | Phase 2 | terminated | Nov 4, 1999 | National Cancer Institute (NCI) | Due to poor accrual and lack of peptide vaccine | Enrollment / accrual |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | Phase 2 | terminated | Feb 15, 2013 | Queen Mary University of London | Inferior efficacy of study drug in renal indication. | Efficacy / futility |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients…(LAK) | — | terminated | Feb 15, 2010 | Loma Linda University | PI left the institution | Investigator |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic… | Phase 1 / Phase 2 | terminated | May 28, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Jul 24, 2013 | University of Colorado, Denver | Sponsor's decision to terminate the study | Sponsor / business decision |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell… | Phase 2 | terminated | Aug 31, 2007 | University of Chicago | Too slow accrual | Enrollment / accrual |
| NCT00802633 | Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact… | N/A | terminated | Dec 5, 2008 | Vanderbilt University | Enrollment was stopped after eighty patients were enrolled. | Enrollment / accrual |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell…(CA9CRM) | — | terminated | Jul 20, 2009 | Centre Hospitalier Universitaire de Saint Etienne | Difficult for recruiting | Enrollment / accrual |
| NCT01639521 | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine,… | Phase 2 | withdrawn | Jul 12, 2012 | University of Southern California | Lack of funding | Funding |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell… | Phase 1 | terminated | Sep 3, 2012 | Seagen Inc. | not stated | Not stated |
| NCT00176501 | Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | Phase 2 | terminated | Sep 15, 2005 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT00014287 | Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer | Phase 1 | withdrawn | Jan 7, 2004 | University of Pittsburgh | not stated | Not stated |
| NCT01496534 | Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients… | Phase 1 | terminated | Dec 21, 2011 | Matthew Galsky | toxicity of combination of medications | Safety / toxicity |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell… | — | terminated | Feb 5, 2010 | Jason Hafron | Preliminary data did not show expected outcomes. | Other (stated, no rule matched) |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | May 9, 2005 | Bayer | not stated | Not stated |
| NCT00289146 | Comparison of Immune Response Following Surgical Management of Renal Tumors | — | terminated | Feb 9, 2006 | Emory University | not stated | Not stated |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally… | Phase 2 | terminated | Sep 20, 2005 | University of Chicago | Study completed | Other (stated, no rule matched) |
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | N/A | terminated | Nov 10, 2009 | New Mexico Cancer Research Alliance | PI deparature and very low (\<2%) accrual rate.(No results required) | Enrollment / accrual |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated… | Phase 2 | terminated | Nov 14, 2007 | Accelerated Community Oncology Research Network | The study was closed to enrollment when it became clear that enrollment was too slow to complete… | Enrollment / accrual |
| NCT00084578 | Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic… | N/A | withdrawn | Jun 11, 2004 | Fox Chase Cancer Center | Withdrawn due to drug toxicity | Safety / toxicity |
| NCT00025519 | Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent… | Phase 2 | withdrawn | Jan 27, 2003 | Fox Chase Cancer Center | not stated | Not stated |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT00516750 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving… | Phase 2 | terminated | Aug 15, 2007 | Kyoto University | Withdrawn due to lack of enrollment. | Enrollment / accrual |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent)… | — | terminated | Feb 23, 2010 | Pfizer | The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no… | Safety / toxicity |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced… | Phase 1 | terminated | Jan 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | Phase 2 | withdrawn | Apr 17, 2013 | Dana-Farber Cancer Institute | Sponsor Aveo has withdrawn support for this trial. | Other (stated, no rule matched) |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | — | withdrawn | Feb 1, 2013 | Pfizer | not stated | Not stated |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Phase 2 | terminated | Jun 25, 2007 | M.D. Anderson Cancer Center | Closed early for poor accrual. | Enrollment / accrual |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in… | — | terminated | Nov 8, 2011 | Dartmouth-Hitchcock Medical Center | Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study. The… | Enrollment / accrual |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Jun 11, 2012 | Andrea Harzstark | not stated | Not stated |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell… | Phase 2 | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow accrual, study terminated. | Enrollment / accrual |
| NCT00601120 | RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic… | N/A | withdrawn | Jan 25, 2008 | Beth Israel Deaconess Medical Center | This protocol was never officially opened and no patients were recruited. | Enrollment / accrual |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced… | Phase 1 | terminated | Jan 5, 2009 | Astellas Pharma Inc | Trial was terminated due to the need to re-formulate the study drug. | Other (stated, no rule matched) |
| NCT00311545 | S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer | Phase 2 | withdrawn | Apr 6, 2006 | SWOG Cancer Research Network | withdrawal of support for drug supply | Drug supply |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to… | Phase 2 | terminated | Jan 1, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | Phase 2 | withdrawn | Oct 4, 2012 | University of Michigan Rogel Cancer Center | Funding issues. | Funding |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | Early Phase 1 | terminated | Nov 22, 2010 | University Hospital, Bordeaux | The rythm of enrollment was not compatible with the objective of recruitement in the research. | Enrollment / accrual |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | Phase 2 | terminated | Jul 12, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Poor Accrual | Enrollment / accrual |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | Phase 2 | terminated | Mar 12, 2012 | Photocure | slow inclusion rate | Other (stated, no rule matched) |
| NCT00492440 | Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or… | Phase 1 | terminated | Jun 27, 2007 | Cytheris SA | not stated | Not stated |
| NCT00042887 | Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00082459 | Trial to Compare the Routes of Administration of an Investigational, Personalized,… | Phase 2 | terminated | May 12, 2004 | Agenus Inc. | Lack of enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 29, 2014source: clinicaltrials